Merck & vs US Dollar/Chinese Yuan FX Spot Rate: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Merck & Company Inc (MRK)

Q3 202630 Jun – 30 Sep 2026

▲3

Merck's Q3: Pipeline Wins and Guidance Raise Offset Keytruda Threats

Keytruda Label Expansions and Phase 3 Wins Merck expanded Keytruda's labels in breast and bladder cancer and reported a Phase 3 win in endometrial cancer. These broaden use and support sales growth, helping offset looming competition.
Shows continued growth for Merck's top drug, a key positive for the quarter.
FDA Approves LIPFENDRA, First Oral PCSK9 Inhibitor Merck won FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor for high cholesterol. This opens a new market and diversifies revenue beyond oncology.
A major new product approval that adds a new growth driver.
Q2 Beat and Raised Full-Year Guidance Merck beat Q2 estimates with $16.61 billion revenue and raised full-year guidance to $66.3–67.3 billion. The strong results and outlook boosted investor confidence.
Directly reflects financial performance and management confidence.
Keytruda Competitive Threats and Other Headwinds Keytruda faces threats from ivonescimab, AstraZeneca's $2 billion Summit investment, and a pre-2028 biosimilar. Also, a congressional probe, generic Janumet XR, lost COVID revenue, and acquisition charges weighed.
Highlights the main risks that could pressure Merck's stock despite positives.

September 202630 Aug – 30 Sep 2026

▲2▼1

Merck's mRNA vaccine and new cholesterol drug shine, but Keytruda threats loom

FDA approves LIPFENDRA, first oral PCSK9 cholesterol drug The FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, offering a new growth driver in a large market and potentially boosting Merck's revenue outlook.
This is a new product approval that expands Merck's commercial portfolio.
Pipeline expansions and label wins Merck advanced its pipeline with tulisokibart, a KRAS licensing deal, and oral delivery technology, while gaining label expansions for Keytruda, Winrevair, and Welireg, offsetting patent-cliff worries.
These moves strengthen Merck's long-term growth prospects and diversify its revenue base.
Keytruda faces competitive threats Keytruda faces mounting threats: Summit's ivonescimab beat it in lung cancer survival, AstraZeneca invested $2 billion in Summit, and a pembrolizumab biosimilar is coming before the 2028 patent expiry.
Keytruda is Merck's top-selling drug, so competition could significantly hurt future revenue.

Latest27 Sep – 30 Sep 2026

▲3▼1

Merck's pipeline wins and deals offset Keytruda competition

Tulisokibart hits Phase 2b goal in skin disease Merck's anti-TL1A drug tulisokibart met its main goal in a mid-stage hidradenitis suppurativa trial, with 72% of high-dose patients responding versus 35% on placebo. This is the first positive Phase 2 result for this drug class in dermatology, opening a new growth area beyond cancer and supporting the stock.
New clinical win shows pipeline diversification beyond Keytruda, a key positive for future revenue.
Merck licenses KRAS cancer drug for up to $2.13B Merck paid $400 million upfront for global rights to SciBrunch's SPR2015, a preclinical KRAS G12D inhibitor for pancreatic, colorectal and lung cancers, with total deal value up to $2.13 billion. This adds a promising early cancer asset, though it will cause a $0.13 per share charge in Q3 results.
New licensing deal expands oncology pipeline, a strategic positive despite a small near-term earnings hit.
Oral drug delivery tech enters human testing MSD began a Phase 1 trial of a proprietary drug using Cyprumed's oral delivery technology, triggering a milestone payment. If successful, this could let Merck turn injectable peptides into pills, a big manufacturing and patient convenience advantage that supports the pipeline.
New technology milestone that could improve drug delivery and extend product lifecycles.
AstraZeneca's $2B bet on Keytruda rival Summit AstraZeneca will invest $2 billion in Summit Therapeutics and lead trials combining Summit's ivonescimab with AstraZeneca's cancer drugs. Ivonescimab has already beaten Keytruda in lung cancer survival, so this deepens the competitive threat to Merck's biggest franchise ahead of its 2028 patent expiry.
New competitive escalation directly pressures Keytruda, Merck's largest revenue source.

20 Sep – 25 Sep 2026

▲3▼1

Merck's Label Wins and Pipeline Progress Offset Keytruda Competition

Multiple FDA and global label expansions for Keytruda, Winrevair, and Welireg Merck won FDA label updates for Winrevair (adding Phase 3 HYPERION data showing 76% reduction in clinical worsening) and Welireg plus Lenvima for advanced kidney cancer, plus Japanese approval for subcutaneous Keytruda across all indications. These expand approved uses and strengthen revenue durability.
These regulatory wins directly broaden Merck's product labels and market reach, supporting future sales growth.
Pipeline advances in remigromig and Keytruda combinations Merck's remigromig met its primary goal in a Phase IIb/III diabetic macular edema study, a first-in-class eye drug. Also, Inhibrx's INBRX-106 combined with Keytruda nearly doubled response rates in head and neck cancer, reinforcing Keytruda's backbone role.
These pipeline successes show Merck's R&D engine is producing new growth drivers beyond current drugs.
Keytruda faces competitive and regulatory setbacks Summit's ivonescimab cut death risk 27% versus Keytruda in lung cancer, a direct threat. Separately, Merck and Daiichi Sankyo withdrew a US application for ifinatamab deruxtecan after FDA said data didn't support accelerated approval, delaying a pipeline candidate.
These events pressure Keytruda's dominance and remove a near-term pipeline catalyst, weighing on sentiment.
Measles outbreak boosts demand for Merck's MMR vaccine A US measles outbreak with 3,471 cases and 95% in unvaccinated people increases demand for Merck's MMR vaccine. This provides a modest but steady revenue lift from an existing product.
Rising disease incidence directly drives higher vaccine sales for Merck.

7 Sep – 18 Sep 2026

▲3▼1

Merck's Pipeline Push and Keytruda Defense Drive the Story

Pipeline triples to offset Keytruda patent cliff Merck's phase III pipeline has nearly tripled since 2021, with 20 new drug launches expected by 2030 to replace Keytruda's 2028 patent loss. Acquisitions like Verona, Cidara and Terns add new growth. This reassures investors that the coming revenue drop may be a shallow dip, supporting the stock.
This is the central strategic force behind Merck's valuation and directly addresses its biggest risk.
Q2 sales beat, guidance raised, Keytruda strong Merck reported Q2 sales of $16.6 billion, with Keytruda franchise at $8.4 billion, and raised full-year 2026 guidance to $66.3–$67.3 billion. Winrevair jumped 75% to $588 million. Solid results and confident outlook support the stock, though a $5.7 billion acquisition charge caused a reported loss.
Earnings and guidance are key fundamental drivers that show current business strength and future expectations.
Keytruda rival shows survival advantage Summit's ivonescimab cut death risk by 27% versus Keytruda in a lung cancer trial, with an 8.2-month survival advantage. This is a direct competitive threat to Merck's biggest drug, pressuring the stock as it raises doubts about Keytruda's long-term dominance.
This is a major competitive development that could erode Keytruda's franchise, a core part of Merck's value.
EU approval advances Keytruda bladder cancer combo EU regulators gave a positive opinion for Keytruda plus Padcev in resectable muscle-invasive bladder cancer, with final approval expected by Q4 2026. This expands Keytruda's use into earlier-stage disease, adding a new revenue stream and strengthening the franchise.
Regulatory progress opens a new market for Keytruda, directly supporting future sales growth.

30 Aug – 4 Sep 2026

▲3▼1

Merck's mRNA cancer vaccine win lifts outlook, but Keytruda rivals close in

mRNA cancer vaccine success drives healthcare rally Merck and Moderna's personalized mRNA cancer vaccine met its main Phase 3 goal in melanoma, cutting recurrence when added to Keytruda. The news sparked a broad healthcare rally, with Merck up 12% in a day and the sector posting its best week since June. This opens a major new growth path for Merck's oncology business.
This is the biggest new event of the period, directly boosting Merck's growth outlook and stock.
Analysts see multi-billion sales potential for vaccine Barclays estimates the vaccine could generate up to $3 billion in annual melanoma sales by 2035, and the global melanoma drug market is projected to grow from $5.8 billion in 2024 to $10.3 billion by 2030. This supports expectations of a meaningful new revenue stream for Merck.
It quantifies the financial upside of the vaccine, which is key to why Merck's stock is moving.
LIPFENDRA approval opens high-growth cholesterol market Merck's LIPFENDRA, the first oral PCSK9 cholesterol drug, has been approved by the FDA, driving the PCSK9 inhibitor market into a high-growth phase. This adds a new cardiometabolic pillar to Merck's business, diversifying revenue beyond Keytruda and supporting long-term growth.
It shows a new approved product expanding Merck's revenue base, which investors view positively.
Keytruda biosimilar and rival lung cancer threat Cipla's US unit secured exclusive rights to commercialize a proposed pembrolizumab biosimilar ahead of Keytruda's 2028 patent expiry. Separately, Summit Therapeutics' ivonescimab showed superior overall survival versus Keytruda in a lung cancer trial. These developments increase competition and pressure Merck's biggest franchise.
It is the main counterweight to the positive news, highlighting risks to Merck's key revenue source.

August 202627 Jul – 28 Aug 2026

▲2▼2

Merck beats Q2, raises guidance, but acquisition charges and mRNA vaccine risks temper outlook

Q2 Beat and Raised Guidance Merck reported Q2 revenue of $16.61 billion, beating estimates, and raised its full-year 2026 revenue guidance to $66.3–67.3 billion, signaling confidence in its core business.
This is a new positive development that directly supports the stock by showing better-than-expected financial performance and improved future outlook.
mRNA Cancer Vaccine Phase 3 Win Merck and Moderna's mRNA cancer vaccine succeeded in a Phase 3 melanoma trial, the first such win, with analysts projecting up to $54 billion in peak sales and testing in nine cancer trials.
This is a major new pipeline breakthrough that could drive long-term growth and is a key reason for investor optimism.
Acquisition Charges Cause Quarterly Loss Multibillion-dollar charges from acquisitions of Bio-Techne, Cidara, and Terns pushed Merck to a quarterly loss, pressuring reported earnings despite the revenue beat.
This new negative factor explains why reported earnings were weak and could weigh on investor sentiment.
mRNA Vaccine Unapproved and Biotech Volatility The mRNA cancer vaccine remains unapproved, so revenue depends on regulatory review, and Moderna's 20% post-surge plunge highlights the volatility of biotech stocks, adding uncertainty.
This new risk factor tempers the positive vaccine news and could lead to stock price swings.

8 Aug – 28 Aug 2026

▲3

Merck Hits 52-Week High on mRNA Cancer Vaccine Win and Pipeline Push

First Phase 3 win for mRNA cancer vaccine with Moderna Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the biggest new catalyst driving MRK's stock to a 52-week high.
Analysts see multi-billion sales potential for the vaccine Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst upgrades and sales estimates directly influence investor expectations and stock price.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
Pipeline expansion reduces reliance on Keytruda and supports long-term growth narrative.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
This counterweight reminds investors that the vaccine is not yet approved and near-term revenue is uncertain.

19 Aug – 20 Aug 2026

▲3

Merck Jumps on First mRNA Cancer Vaccine Win with Moderna

Phase 3 mRNA cancer vaccine success Merck and Moderna's personalized mRNA cancer vaccine met its main goal in a Phase 3 melanoma trial, cutting recurrence when added to Keytruda. This is the first late-stage win for an mRNA cancer therapy, opening a new growth path for Merck's oncology business.
This is the single new event that drove Merck's stock up over 11% and sets up a potential new product.
Analysts see multi-billion sales potential Bank of America raised its peak sales estimate for the vaccine to $54 billion and upgraded Moderna, noting Merck shares 50% of the economics. Barclays sees about $3 billion in annual melanoma sales by 2035. This supports expectations of a meaningful new revenue stream.
Analyst estimates quantify the financial upside for Merck, reinforcing the positive stock reaction.
Broader pipeline expansion across cancers The companies are testing the vaccine-Keytruda combo in nine Phase 2 and Phase 3 trials covering lung, bladder, kidney, pancreatic and gastric cancers. Success in more tumor types would further extend Keytruda's franchise and diversify Merck's revenue beyond its current uses.
It shows the win is not a one-off but part of a larger strategy that could drive long-term growth.
Moderna's sharp reversal shows volatility Moderna shares plunged 20% the day after a 177% surge, a reminder that early-stage biotech wins can be volatile. For Merck, the milestone is real but the vaccine is not approved yet, and near-term revenue depends on regulatory review and further trial results.
It provides a fair counterweight: the excitement is justified but not without risk, and Merck's own stock move was more measured.

27 Jul – 6 Aug 2026

▲3

Merck Beats Q2, Raises Guidance as Keytruda and New Drugs Expand

Q2 Beat and Raised 2026 Guidance Merck reported Q2 revenue of $16.61 billion, up 5% and above estimates, with Keytruda sales of $8.37 billion. Management raised full-year 2026 revenue guidance to $66.3–$67.3 billion. This directly boosts investor confidence and supports a higher stock price.
This is the period's biggest new financial catalyst, showing stronger-than-expected results and a brighter outlook.
Keytruda Label Expansions in Canada and EU Diagnostic Health Canada approved Keytruda with enfortumab vedotin for bladder cancer, and Agilent's EU companion diagnostic helps identify more patients for Keytruda. These expand Keytruda's use into new patient groups, supporting future sales growth as Merck faces eventual patent expiration.
New approvals and diagnostic tools widen Keytruda's market, a key growth driver for Merck.
New Drug Approvals and Pipeline Progress FDA approved LIPFENDRA, the first oral PCSK9 cholesterol drug, adding a new cardiometabolic pillar. Merck also advanced HIV prevention access and reported positive Phase 3 results for a once-weekly HIV regimen. These diversify revenue beyond Keytruda and support long-term growth.
These new products and pipeline wins show Merck building future revenue streams, reducing reliance on Keytruda.
Acquisition Charges Weigh on Reported Earnings Merck's $11.3 billion Bio-Techne and $9 billion Cidara acquisitions, plus a $5.7 billion Terns charge, caused a reported quarterly loss. While these deals aim to replenish the pipeline, the large cash outlays and charges pressure near-term reported profits and could weigh on sentiment.
This is the main counterweight: big spending and accounting losses offset strong operational results.

July 202630 Jun – 24 Jul 2026

▲2▼2

Merck's Pipeline Wins Offset Generic and Regulatory Pressures

Keytruda Label Expansion and Phase 3 Win Keytruda won U.S. and EU approvals in breast and bladder cancer and succeeded in a Phase 3 endometrial cancer trial, expanding its use and supporting future sales.
This is a major new positive driver for Merck's top-selling drug.
New Drug Approvals and HIV Advancements The FDA approved LIPFENDRA, the first oral PCSK9 inhibitor, and Merck advanced HIV efforts with Gilead and an access plan, broadening its treatment portfolio.
These are new pipeline and label wins that could drive future revenue.
Congressional Probe into China Trials A U.S. House committee is investigating Merck's China clinical trials, raising concerns about ethics, data security, and intellectual property that could harm its reputation and operations.
This is a new regulatory and geopolitical risk that could weigh on the stock.
Generic Competition and COVID Revenue Loss Par Health launched a generic version of Janumet XR, eroding about $270 million in annual U.S. sales, while COVID-19 EUA termination removed Lagrevio revenue, pressuring overall sales.
These are new negative developments that directly reduce Merck's revenue.

15 Jul – 24 Jul 2026

▲3▼1

Merck's Pipeline Wins Outweigh Generic Erosion

Keytruda Endometrial Cancer Win Merck's Keytruda met its main goal in a Phase 3 endometrial cancer trial, showing better progression-free survival than chemotherapy. This expands Keytruda's use into a new cancer type, supporting future sales as the company faces patent expiration.
New clinical win expands Keytruda's label and supports long-term revenue.
FDA Approves First Oral PCSK9 Inhibitor LIPFENDRA Merck won FDA approval for LIPFENDRA, the first once-daily oral PCSK9 inhibitor for high cholesterol. It cut LDL-C by up to 59% in trials and offers an easier option than injectables, opening a large new market for Merck.
New product approval opens a major new revenue stream beyond oncology.
HIV Pipeline Advances with Gilead and Access Plan Merck and Gilead reported positive Phase 3 results for a once-weekly oral HIV regimen, and Merck unveiled an early access plan for its once-monthly HIV prevention pill in 129 low- and middle-income countries. These moves strengthen Merck's HIV franchise and future demand.
New HIV data and access strategy expand Merck's pipeline and global reach.
Generic Janumet XR Launch Erodes Sales Par Health launched the first generic version of Merck's Janumet XR diabetes drug in the U.S. This will cut into Merck's sales of the branded product, which had about $270 million in annual U.S. revenue, as cheaper copies take market share.
New generic competition directly pressures an existing Merck product's revenue.

30 Jun – 10 Jul 2026

▲2▼2

Merck's Keytruda Label Wins Offset China Probe and COVID Drug Loss

U.S. House Committee Probes Merck's China Clinical Trials A House committee is investigating Merck's clinical trials at Chinese military sites and in Xinjiang, raising concerns about ethics, data security, and intellectual property. This regulatory and headline risk could weigh on the stock, especially if it leads to restrictions or reputational damage.
This is a new negative regulatory event that introduces uncertainty and potential downside for MRK.
COVID-19 EUA Termination Hits Merck's Lagrevio The U.S. government ended emergency use authorizations for COVID-19 drugs, including Merck's Lagrevio. This removes a revenue stream and could lower future sales expectations, though the impact may be limited if COVID-19 remains endemic and traditional approvals are pursued.
This is a new regulatory change that directly reduces Merck's COVID-19 product sales.
Keytruda Wins New U.S. and EU Approvals in Breast and Bladder Cancer Merck received FDA and EU approvals for Keytruda-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer, including a subcutaneous form. These expand Keytruda's label into earlier and tougher tumors, supporting sales growth as the company prepares for patent expiration.
These new approvals broaden Keytruda's market and reinforce Merck's oncology strategy, a key positive driver.
Tulisokibart Phase 3 Success Strengthens Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met its main goal in a Phase 3 ulcerative colitis trial. This is a first for this drug class and helps diversify Merck beyond oncology, offsetting future Keytruda competition and supporting long-term growth.
This pipeline win is a new positive development that boosts Merck's diversification efforts.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

June 202617 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

17 Jun – 26 Jun 2026

▲3▼1

Merck's Pipeline and Label Wins Offset Medicare Pricing Threat

Tulisokibart Phase 3 Win Boosts Immunology Pipeline Merck's anti-TL1A antibody tulisokibart met the main goal in a Phase 3 ulcerative colitis trial, a first for this type of drug. This strengthens Merck's pipeline beyond cancer and helps offset future Keytruda competition, supporting the stock.
This is a new positive pipeline event that directly addresses Merck's post-Keytruda growth story.
FDA and EU Approvals Expand Keytruda, Welireg, and Capvaxive Labels Merck won new approvals for Keytruda+Welireg in kidney cancer, Capvaxive in children, and Keytruda+Padcev in bladder cancer in the EU. These expand patient populations and should lift sales of these drugs.
These are new regulatory wins that broaden Merck's marketed products and drive revenue growth.
Proposed CMS Rule to Make Medicare Drug Price Negotiations Permanent A proposed CMS rule would make Medicare drug price negotiations permanent, directly pressuring Merck's pricing. This regulatory overhang could cap future revenue growth and weighs on the stock.
This is a new regulatory threat that could negatively impact Merck's pricing and profits.
Abu Dhabi Logistics Hub to Expand Regional Distribution Merck (MSD) is partnering with Abu Dhabi to explore a regional logistics hub, which could improve supply chain resilience and access to its therapies in the Middle East. This supports long-term demand.
This new partnership could enhance Merck's distribution and market access in a growing region.

US Dollar/Chinese Yuan FX Spot Rate (USDCNY.FOREX)

Q3 202613 Jul – 22 Sep 2026

▲2▼1

PBOC easing and US-China frictions drove USDCNY in Q3 2026

PBOC easing and record liquidity injection The PBOC's easing bias and record liquidity injection early in the quarter pushed USDCNY higher, as more yuan in the system reduced its value. This was the main upward force on the dollar-yuan rate.
This policy move directly increased USDCNY by weakening the yuan.
Record US-China yield gap and Beijing's efforts to curb yuan strength A record 312 basis point yield gap between US and Chinese bonds made dollar assets more attractive, boosting USDCNY. Beijing's attempts to limit yuan appreciation also kept the dollar stronger versus the yuan.
These factors increased demand for dollars over yuan, lifting USDCNY.
PBOC firmer fixings and yuan hits 3.5-year high In late September, the PBOC shifted to firmer daily fixings, allowing the yuan to reach a 3.5-year high ahead of the Xi-Trump summit. This policy change strengthened the yuan, pushing USDCNY lower.
This policy shift directly strengthened the yuan, lowering USDCNY.
Yuan internationalization and offshore market growth Deutsche Bank's yuan clearing role and Hong Kong's growing offshore turnover supported the yuan by increasing its global use. However, weak Chinese credit and Fed hawkishness limited these gains, keeping USDCNY supported.
This shows both downward pressure on USDCNY from internationalization and upward pressure from weak credit and Fed policy.

September 20265 Sep – 22 Sep 2026

▼3▲1

Beijing now tolerates yuan strength ahead of Xi-Trump summit

PBOC shifts to stronger fixings, yuan hits 3.5-year high The PBOC set firmer-than-expected daily reference rates for five straight days and then let the yuan trade at its strongest since 2022. This official tolerance, ahead of the Xi-Trump meeting, directly pushes USDCNY down (yuan up).
This is the main new force: the central bank stopped restraining yuan appreciation, reversing the earlier stance.
PBOC expands offshore yuan market and liquidity The PBOC pledged to grow the offshore yuan market, keep liquidity ample, and regularize offshore bond and bill sales. More yuan available and usable abroad raises demand for the currency, weighing on USDCNY.
A new official push to internationalize the yuan increases its global use and supports its value.
Hong Kong five-year plan boosts yuan internationalization Hong Kong's first five-year plan expands offshore yuan products and cross-border investment links like Stock Connect. This creates more ways for global investors to hold and use yuan, supporting the currency and pushing USDCNY lower.
A new policy step that adds to structural demand for the yuan.
Weak Chinese credit and Fed hawkishness limit yuan gains August bank lending badly missed forecasts and money growth slowed, while the PBOC held rates and the Fed signaled more hikes. Weak domestic demand and a wide yield gap keep capital attracted to dollars, a real counterweight to yuan strength.
This is the main opposing force that could stop USDCNY from falling further.

Latest5 Sep – 22 Sep 2026

▼3▲1

Beijing now tolerates yuan strength ahead of Xi-Trump summit

PBOC shifts to stronger fixings, yuan hits 3.5-year high The PBOC set firmer-than-expected daily reference rates for five straight days and then let the yuan trade at its strongest since 2022. This official tolerance, ahead of the Xi-Trump meeting, directly pushes USDCNY down (yuan up).
This is the main new force: the central bank stopped restraining yuan appreciation, reversing the earlier stance.
PBOC expands offshore yuan market and liquidity The PBOC pledged to grow the offshore yuan market, keep liquidity ample, and regularize offshore bond and bill sales. More yuan available and usable abroad raises demand for the currency, weighing on USDCNY.
A new official push to internationalize the yuan increases its global use and supports its value.
Hong Kong five-year plan boosts yuan internationalization Hong Kong's first five-year plan expands offshore yuan products and cross-border investment links like Stock Connect. This creates more ways for global investors to hold and use yuan, supporting the currency and pushing USDCNY lower.
A new policy step that adds to structural demand for the yuan.
Weak Chinese credit and Fed hawkishness limit yuan gains August bank lending badly missed forecasts and money growth slowed, while the PBOC held rates and the Fed signaled more hikes. Weak domestic demand and a wide yield gap keep capital attracted to dollars, a real counterweight to yuan strength.
This is the main opposing force that could stop USDCNY from falling further.

August 202611 Aug – 4 Sep 2026

▲2▼1

PBOC caps yuan gains as yield gap and weak data lift USDCNY

Record US-China yield gap pulls capital to dollars A record 312 basis point gap between US and Chinese bond yields makes dollar assets more attractive, pulling capital toward the dollar and pushing USDCNY higher.
This yield differential is a key new force driving USDCNY upward in 2026-08.
Beijing actively curbs yuan strength to protect exports Beijing is using weaker daily fixings and state-bank dollar buying to limit yuan appreciation and protect exporters, adding upward pressure on USDCNY.
This official pushback is a new driver limiting yuan gains and lifting USDCNY.
Yuan internationalization deepens offshore demand Deutsche Bank becoming Europe's first yuan clearing bank and Hong Kong's yuan turnover surpassing its local dollar pair deepen offshore demand, weighing on USDCNY.
This new internationalization milestone supports the yuan and counters upward pressure on USDCNY.
US trade pressure and yuan-expansion subsidies support yuan US trade pressure and Beijing's subsidies to expand yuan usage abroad support the currency over time, acting as a counterweight to upward pressure on USDCNY.
This new factor provides a counterweight to USDCNY's rise, balancing the outlook.

25 Aug – 4 Sep 2026

▲3▼1

Beijing Acts to Slow Yuan's Rise as US Yield Gap Widens

Beijing actively curbs yuan strength to protect exports The yuan has climbed about 9% against the dollar in 20 months, but the PBOC is setting its daily reference rate weaker than markets expect and state banks are buying dollars. This official pushback limits further yuan gains, keeping USDCNY from falling much more.
This is the clearest new signal that authorities want to cap yuan appreciation, directly limiting downside for USDCNY.
Widening US-China yield gap pulls money toward dollars The 10-year US bond yield has jumped to 4.81% while China's stays near 1.69%, a gap of 312 basis points close to a record. Higher US yields make dollar assets more attractive, encouraging capital outflows from China and pushing USDCNY up.
This is a major new market force widening the return gap between the two currencies, favoring the dollar.
Chinese banks buy US Treasuries, slowing yuan appreciation Chinese banks are raising dollar deposit rates above 3% and buying US government bonds for the higher yield. This keeps dollars in China instead of being converted to yuan, easing upward pressure on the Chinese currency and supporting USDCNY.
This new bank behavior is a concrete channel through which capital stays in dollars, reducing yuan demand.
US pressure and yuan internationalization push back the other way Washington is urging G20 action on China's trade surplus and threatening sanctions, while Beijing expands yuan use through subsidies and clearing banks. These steps support the yuan over time, a real counterweight to the forces pushing USDCNY up.
It shows the genuine opposing forces that could strengthen the yuan, giving a fair two-sided picture.

11 Aug – 19 Aug 2026

▼3▲1

PBOC pushes yuan internationalization while weak data and low yields pull money away

PBOC five-year plan backs yuan internationalization and stability The PBOC's new five-year plan promises to keep the yuan basically stable and expand its use in global trade and investment. That supports demand for the Chinese currency, which pushes USDCNY down.
This is a new official policy signal that directly supports the yuan and answers what is driving USDCNY.
Deutsche Bank becomes first European yuan clearing bank Deutsche Bank will clear yuan trades in Frankfurt, making it easier for European firms to use the Chinese currency. More offshore yuan use means more demand for CNY, a downward pull on USDCNY.
A concrete new step in yuan internationalization that adds real demand for the currency.
Yuan becomes Hong Kong's most traded currency pair For the first time, US dollar/yuan trading in Hong Kong beat the local dollar pair, with daily turnover jumping to $274 billion. Deeper offshore yuan trading supports the currency and weighs on USDCNY.
Shows a structural rise in yuan trading activity, a new sign of growing global use.
Weak Chinese data and low yields pull money away from yuan Chinese firms slowed selling foreign currency, and bond yields fell as weak July data boosted easing bets. With US yields high, money prefers dollars over yuan, pushing USDCNY up.
This is the main counterweight: weak economy and low rates are the biggest force lifting USDCNY.

July 202613 Jul – 5 Aug 2026

▲2▼2

PBOC easing bias and US friction lift USDCNY; internationalization counters

PBOC leans against yuan strength The PBOC fixed the midpoint 581 pips weaker than forecasts and injected record liquidity, signaling a preference for a weaker yuan. This easing bias pushed USDCNY higher.
This is a key new policy action that directly weakened the yuan.
US keeps China on currency watchlist The US retained China on its currency watchlist, adding mild political pressure. This friction contributed to USDCNY's upward move.
This is a new geopolitical development that supported the dollar.
Yuan internationalization and gold demand support Ongoing efforts to internationalize the yuan and strong gold demand provided support for the Chinese currency, acting as a counterweight to upward pressure on USDCNY.
This counterforce helped limit yuan weakness.
Exporter pain and European pressure Chinese exporters reported losses from yuan strength, and Europe pressured Beijing over the currency's undervaluation. These factors acted as counterweights to USDCNY's rise.
These are new developments that opposed the upward move.

24 Jul – 5 Aug 2026

▲3▼1

PBOC leans against yuan strength as US keeps China on watchlist

PBOC fixes midpoint much weaker than forecasts On July 31 the PBOC set the yuan's daily reference rate 581 pips weaker than market estimates, the widest gap in five months. This signals Beijing wants to slow or stop the yuan's rise, which pushes USDCNY up.
This is the clearest new signal of official intent to cap yuan appreciation, directly lifting USDCNY.
PBOC injects record liquidity and keeps easing The PBOC pumped 1.2 trillion yuan of medium-term cash in July, the most since February, and on August 2 promised timely policy adjustments and ample liquidity. More money sloshing around lowers Chinese rates, making the yuan less attractive and pushing USDCNY up.
Large liquidity injections and an easing bias are a core force weakening the yuan versus the dollar.
US keeps China on currency watchlist The US Treasury again flagged China for opaque exchange-rate policy, though no sanctions followed. The label adds political friction and mild pressure on the yuan, a small upward nudge for USDCNY rather than a market-moving shock.
It is a new geopolitical/regulatory factor that slightly raises the risk premium on the yuan.
Yuan internationalization and gold demand support CNY The PBOC pushed panda bonds and Hong Kong's offshore yuan hub, while mBridge moved toward commercial use for the digital yuan. Strong gold imports also showed solid yuan demand. These slow-building forces support the yuan and pull USDCNY down, a counterweight to PBOC easing.
It is the main counterweight: structural steps that raise global yuan use and demand, working against the weaker-yuan forces.

13 Jul – 14 Jul 2026

▼3▲1

Yuan firms as PBOC signals comfort with gradual appreciation; exporters feel the pain

PBOC fix below 6.80 signals comfort with yuan strength The PBOC set the yuan's daily reference rate stronger than 6.80 per dollar for the first time since February 2023. That tells markets China's central bank is comfortable letting the yuan rise gradually, which pulls USDCNY down (yuan strengthens).
This is the clearest new policy signal directly pushing the exchange rate lower.
A wave of Chinese exporters reports yuan-driven losses At least eight listed Chinese manufacturers — including Linglong Tire, Topband and Yindu Kitchen — blamed first-half profit drops on yuan appreciation causing exchange losses. This confirms the yuan has genuinely strengthened, but their pain is a counterweight that may slow further gains.
It shows the real economic cost of yuan strength, a genuine counterweight to further appreciation.
Europe calls yuan undervalued, pressuring Beijing on FX policy German Chancellor Merz said the yuan is 20-30% undervalued and urged dialogue on currency policy. International pressure of this kind can push Beijing toward letting the yuan appreciate more freely, which would lower USDCNY over time.
It adds a new geopolitical force that could nudge China toward allowing more yuan strength.
Dollar supported by Fed hike bets and Middle East tensions Safe-haven demand from US-Iran tensions and a 62% market-implied chance of a September Fed rate hike lifted the dollar index. A stronger dollar pushes USDCNY up, but the PBOC's fixing kept the yuan nearly flat, showing the counterweight.
It is the main force pulling the other way, keeping the picture balanced.

Q2 202617 Jun – 9 Jul 2026

▼2▲1

Yuan firms on PBOC internationalization, weak China data, and tech tensions

PBOC pushes Hong Kong as offshore yuan hub The PBOC announced structural measures to make Hong Kong the main offshore yuan center. More offshore yuan use and demand can strengthen the Chinese currency, pushing USDCNY lower. This is a slow-building force, not a one-day move.
Directly affects yuan internationalization and demand, a key long-term driver of USDCNY.
China's economy cools, weighing on yuan May industrial profit growth slowed to 21.1%, and June consumer inflation hit a three-month low of 1.0%, missing forecasts. Weak consumer demand and soft momentum make the yuan less attractive, pushing USDCNY up.
Shows weakening Chinese economic fundamentals that pressure the yuan lower versus the dollar.
Yuan appreciation hurts Chinese exporters Great Star Technology said the yuan's roughly 4.9% rise against the dollar caused over 100 million yuan in exchange losses, hurting margins. This highlights how a stronger yuan squeezes exporters, a counterweight that may slow further yuan gains.
Illustrates real economic pain from yuan strength, a factor that can limit further CNY appreciation.
US-China tech tensions cut both ways Ark Invest sold $54 million of Alibaba after a US military designation, adding geopolitical risk that can weaken the yuan. But Apple is testing Chinese memory chips and lobbying for broader use, which could ease tensions and support the yuan.
Captures opposing geopolitical forces that pull USDCNY in different directions.

June 202617 Jun – 9 Jul 2026

▼2▲1

Yuan firms on PBOC internationalization, weak China data, and tech tensions

PBOC pushes Hong Kong as offshore yuan hub The PBOC announced structural measures to make Hong Kong the main offshore yuan center. More offshore yuan use and demand can strengthen the Chinese currency, pushing USDCNY lower. This is a slow-building force, not a one-day move.
Directly affects yuan internationalization and demand, a key long-term driver of USDCNY.
China's economy cools, weighing on yuan May industrial profit growth slowed to 21.1%, and June consumer inflation hit a three-month low of 1.0%, missing forecasts. Weak consumer demand and soft momentum make the yuan less attractive, pushing USDCNY up.
Shows weakening Chinese economic fundamentals that pressure the yuan lower versus the dollar.
Yuan appreciation hurts Chinese exporters Great Star Technology said the yuan's roughly 4.9% rise against the dollar caused over 100 million yuan in exchange losses, hurting margins. This highlights how a stronger yuan squeezes exporters, a counterweight that may slow further yuan gains.
Illustrates real economic pain from yuan strength, a factor that can limit further CNY appreciation.
US-China tech tensions cut both ways Ark Invest sold $54 million of Alibaba after a US military designation, adding geopolitical risk that can weaken the yuan. But Apple is testing Chinese memory chips and lobbying for broader use, which could ease tensions and support the yuan.
Captures opposing geopolitical forces that pull USDCNY in different directions.

17 Jun – 9 Jul 2026

▼2▲1

Yuan firms on PBOC internationalization, weak China data, and tech tensions

PBOC pushes Hong Kong as offshore yuan hub The PBOC announced structural measures to make Hong Kong the main offshore yuan center. More offshore yuan use and demand can strengthen the Chinese currency, pushing USDCNY lower. This is a slow-building force, not a one-day move.
Directly affects yuan internationalization and demand, a key long-term driver of USDCNY.
China's economy cools, weighing on yuan May industrial profit growth slowed to 21.1%, and June consumer inflation hit a three-month low of 1.0%, missing forecasts. Weak consumer demand and soft momentum make the yuan less attractive, pushing USDCNY up.
Shows weakening Chinese economic fundamentals that pressure the yuan lower versus the dollar.
Yuan appreciation hurts Chinese exporters Great Star Technology said the yuan's roughly 4.9% rise against the dollar caused over 100 million yuan in exchange losses, hurting margins. This highlights how a stronger yuan squeezes exporters, a counterweight that may slow further yuan gains.
Illustrates real economic pain from yuan strength, a factor that can limit further CNY appreciation.
US-China tech tensions cut both ways Ark Invest sold $54 million of Alibaba after a US military designation, adding geopolitical risk that can weaken the yuan. But Apple is testing Chinese memory chips and lobbying for broader use, which could ease tensions and support the yuan.
Captures opposing geopolitical forces that pull USDCNY in different directions.